Medpace Holdings, Inc. (MEDP)
USD 296.77
(5.11%)
USD 296.77
(5.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -103.32 Million USD | -164.34% |
| 2022 | 160.6 Million USD | 148.62% |
| 2021 | -330.33 Million USD | -103.13% |
| 2020 | -162.62 Million USD | -87.55% |
| 2019 | -86.7 Million USD | -253.61% |
| 2018 | 56.44 Million USD | -71.07% |
| 2017 | 195.12 Million USD | 54.2% |
| 2016 | 126.54 Million USD | -65.14% |
| 2015 | 363 Million USD | -16.98% |
| 2014 | 437.23 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -528.62 Million USD | -48.0% |
| 2024 Q2 | -357.16 Million USD | -31.87% |
| 2024 Q1 | -270.85 Million USD | -162.13% |
| 2023 Q1 | 210.76 Million USD | 31.24% |
| 2023 Q3 | 47.83 Million USD | -69.19% |
| 2023 Q4 | -103.32 Million USD | -316.02% |
| 2023 FY | -103.32 Million USD | -164.34% |
| 2023 Q2 | 155.25 Million USD | -26.34% |
| 2022 Q1 | 58.78 Million USD | 117.79% |
| 2022 Q4 | 160.6 Million USD | -35.21% |
| 2022 Q2 | 342.12 Million USD | 482.04% |
| 2022 FY | 160.6 Million USD | 148.62% |
| 2022 Q3 | 247.89 Million USD | -27.54% |
| 2021 Q1 | -218.73 Million USD | -34.5% |
| 2021 FY | -330.33 Million USD | -103.13% |
| 2021 Q4 | -330.33 Million USD | -22.27% |
| 2021 Q3 | -270.17 Million USD | -19.46% |
| 2021 Q2 | -226.15 Million USD | -3.4% |
| 2020 Q3 | -108.55 Million USD | -136.41% |
| 2020 FY | -162.62 Million USD | -87.55% |
| 2020 Q4 | -162.62 Million USD | -49.8% |
| 2020 Q2 | -45.91 Million USD | 44.41% |
| 2020 Q1 | -82.6 Million USD | 4.73% |
| 2019 Q3 | -33.26 Million USD | -240.77% |
| 2019 Q1 | 71.89 Million USD | 27.36% |
| 2019 Q4 | -86.7 Million USD | -160.63% |
| 2019 FY | -86.7 Million USD | -253.61% |
| 2019 Q2 | 23.63 Million USD | -67.13% |
| 2018 Q4 | 56.44 Million USD | -38.27% |
| 2018 Q2 | 141.29 Million USD | -19.41% |
| 2018 Q1 | 175.32 Million USD | -10.15% |
| 2018 FY | 56.44 Million USD | -71.07% |
| 2018 Q3 | 91.44 Million USD | -35.28% |
| 2017 Q3 | 160.45 Million USD | 24.79% |
| 2017 Q2 | 128.57 Million USD | -2.09% |
| 2017 Q4 | 195.12 Million USD | 21.61% |
| 2017 FY | 195.12 Million USD | 54.2% |
| 2017 Q1 | 131.32 Million USD | 3.78% |
| 2016 Q1 | 354.27 Million USD | -2.4% |
| 2016 Q4 | 126.54 Million USD | -9.6% |
| 2016 Q3 | 139.97 Million USD | -60.05% |
| 2016 FY | 126.54 Million USD | -65.14% |
| 2016 Q2 | 350.35 Million USD | -1.11% |
| 2015 Q1 | 54.28 Million USD | 0.0% |
| 2015 FY | 363 Million USD | -16.98% |
| 2015 Q4 | 363 Million USD | 0.0% |
| 2014 FY | 437.23 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | -161.906% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | -1647.147% |
| Aspira Women's Health Inc. | -331 Thousand USD | -31116.616% |
| Biodesix, Inc. | 34.3 Million USD | 401.183% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | -1682.748% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -8213.173% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -8213.173% |
| Bionano Genomics, Inc. | 34.88 Million USD | 396.219% |
| CareDx, Inc | -47.97 Million USD | -115.372% |
| Check-Cap Ltd. | -24.75 Million USD | -317.382% |
| Castle Biosciences, Inc. | -83.53 Million USD | -23.699% |
| DarioHealth Corp. | -7.54 Million USD | -1268.932% |
| Exact Sciences Corporation | 1.94 Billion USD | 105.301% |
| Fulgent Genetics, Inc. | -82.56 Million USD | -25.145% |
| Guardant Health, Inc. | 220.22 Million USD | 146.918% |
| ICON Public Limited Company | 3.56 Billion USD | 102.902% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 120.919% |
| Illumina, Inc. | 1.21 Billion USD | 108.511% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | -1801.96% |
| iSpecimen Inc. | -2.14 Million USD | -4711.677% |
| Standard BioTools Inc. | 46.5 Million USD | 322.18% |
| MDxHealth SA | 18.88 Million USD | 647.138% |
| 23andMe Holding Co. | -141.37 Million USD | 26.911% |
| Myriad Genetics, Inc. | 88.1 Million USD | 217.284% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 29634.236% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | -4135.574% |
| NeoGenomics, Inc. | 269.19 Million USD | 138.384% |
| Neogen Corporation | 735.62 Million USD | 114.046% |
| Inotiv, Inc. | 382.14 Million USD | 127.038% |
| Natera, Inc. | -200.1 Million USD | 48.363% |
| OpGen, Inc. | 11.89 Million USD | 968.887% |
| OPKO Health, Inc. | 230.68 Million USD | 144.792% |
| Psychemedics Corporation | 334 Thousand USD | 31036.228% |
| Prenetics Global Limited | -43.33 Million USD | -138.426% |
| Prenetics Global Limited | -43.33 Million USD | -138.426% |
| Precipio, Inc. | -386 Thousand USD | -26668.653% |
| Personalis, Inc. | -8.02 Million USD | -1188.045% |
| RadNet, Inc. | 1.14 Billion USD | 108.996% |
| Sera Prognostics, Inc. | -2.02 Million USD | -5010.138% |
| Sotera Health Company | 2.02 Billion USD | 105.102% |
| Neuronetics, Inc. | 2.79 Million USD | 3794.208% |
| Star Equity Holdings, Inc. | -15.33 Million USD | -573.711% |
| Star Equity Holdings, Inc. | -15.33 Million USD | -573.711% |
| Trinity Biotech plc | 63.73 Million USD | 262.117% |
| T2 Biosystems, Inc. | 33.8 Million USD | 405.62% |
| Twist Bioscience Corporation | -192.4 Million USD | 46.296% |
| Exagen Inc. | -12.77 Million USD | -709.012% |